Auflistung nach Autor "Sadeghlar, Farsaneh"
Anzeige der Dokumente 1-7 von 7
-
Comparison between regular additional endobiliary radiofrequency ablation and photodynamic therapy in patients with advanced extrahepatic cholangiocarcinoma under systemic chemotherapy
(2023-08-29)<strong>Background and aims: </strong>Extrahepatic cholangiocarcinoma (eCCA) remains a malignancy with a dismal prognosis. The first-line standard of care includes systemic chemotherapy (SC) and biliary drainage through ... -
Deficient immune response following SARS-CoV-2 vaccincation in patients with hepatobiliary carcinoma: A forgotten, vulnerable group of patients
(2023-05-10)<strong>Introduction:</strong> Data on immune response rates following vaccination for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in patients with hepatobiliary carcinoma (HBC) are rare. However, impaired ... -
First-Line Treatment for Advanced Hepatocellular Carcinoma: A Three-Armed Real-World Comparison
(2024-01-13)<strong>Background and Aim:</strong> There are several existing systemic 1st- line therapies for advanced hepatocellular carcinoma (HCC), including atezolizumab/bevacizumab (Atez/Bev), sorafenib and lenvatinib. This study ... -
Impaired immunogenicity after vaccination for SARS-CoV-2 in patients with gastrointestinal cancer: does tumor entity matter?
(2023-06-26)<strong>Background:</strong> SARS-CoV-2 immunogenicity in patients with gastrointestinal cancer (GI cancer) following second and third vaccination was analyzed.<br /> <strong>Methods:</strong> A total of 125 patients under ... -
Longitudinal Study of SARS-CoV-2 Vaccinations and Infections in Patients with Gastrointestinal Cancer: Stabilizing Immune Responses and Neutralizing Emerging Variants with Variant-Adapted Antigen Exposures
(2024-12-19)This longitudinal study examined how active gastrointestinal (GI) cancer types affect immune responses to SARS-CoV-2, focusing on the ability to neutralize the Omicron variants. Patients with GI cancer (<em>n</em> = 168) ... -
Regulatory T Cell Inhibition by P60 Combined with Adenoviral AFP Transduced Dendritic Cells for Immunotherapy of Hepatocellular Carcinoma
(2023-10-17)<strong>Background & Aims:</strong> Vaccination with tumor-associated antigen-pulsed dendritic cells leads to specific T-cell response against hepato-cellular carcinoma. However, clinical response has been shown to be ... -
Second-line and third-line therapy with nanoliposomal irinotecan (nal-IRI) in pancreatic cancer: a single-center experience and review of literature
(2023-02-15)Background: Prognosis of patients with pancreatic cancer is still extremely poor. First-line palliative therapies with FOLFIRINOX or gemcitabine/nab-paclitaxel have been established in the last decade. In the second-line, ...
